Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores

Research output: Contribution to journalArticle

Authors

  • Marco Proietti
  • José Miguel Rivera-Caravaca
  • María Asunción Esteve-Pastor
  • Giulio Francesco Romiti
  • Francísco Marin

Colleges, School and Institutes

External organisations

  • 2 Department of Neuroscience IRCCS-Istituto di Ricerche Farmacologiche Mario Negri Milan Italy.
  • 3 Department of Cardiology Hospital Clínico Universitario Virgen de la Arrixaca Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBER-CV Murcia Spain.
  • 4 Department of Internal Medicine and Medical Specialties Sapienza-University of Rome Rome Italy.
  • 1 Institute of Cardiovascular Sciences University of Birmingham Birmingham United Kingdom.
  • 5 Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart & Chest Hospital Liverpool UK.
  • 6 Aalborg Thrombosis Research Unit Department of Clinical Medicine Aalborg University Aalborg Denmark.

Abstract

Background Patients with atrial fibrillation (AF) treated with oral anticoagulants may be exposed to an increased risk of bleeding events. The HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INRs, Elderly, Drugs or alcohol) score is a simple, well-established, clinical bleeding-risk prediction score. Recently, a new algorithm-based score was proposed, the GARFIELD-AF (Global Anticoagulant in the Field-AF) bleeding score. We compared HAS-BLED and GARFIELD-AF scores in predicting adjudicated bleeding events in a clinical trial cohort of patients with AF taking anticoagulants, in the first external comparative validation of both scores. Methods and Results We analyzed patients from the SPORTIF (Stroke Prevention Using an Oral Thrombin Inhibitor in Patients With AF) III and V trials. All patients assigned to the warfarin arm with information to calculate the scores were considered. Outcomes were major, major/clinically relevant nonmajor, and any bleeding. A total of 3550 warfarin-treated patients were available for analysis. Of these patients, 2519 (71.0%) had a HAS-BLED score ≥3, whereas based on GARFIELD-AF median value, 2056 (57.9%) were categorized as "high score." Both HAS-BLED and GARFIELD-AF C-indexes showed modest predictive value (C-index [95% confidence interval] for major bleeding, 0.58 [0.56-0.60] and 0.56 [0.54-0.57], respectively); however, GARFIELD-AF was not predictive of any bleeding. The GARFIELD-AF bleeding score had a significantly lower sensitivity and a negative reclassification for any bleeding compared with HAS-BLED, assessed by integrated discrimination improvement and net reclassification improvement (both P<0.001). HAS-BLED showed a 5% net benefit for any bleeding occurrence. Conclusions The algorithm-based GARFIELD-AF bleeding score did not show any significant improvement in major and major/clinically relevant nonmajor prediction compared with the simple HAS-BLED score. For clinical usefulness in prediction of any bleeding, the HAS-BLED score showed a significant net benefit compared with the GARFIELD-AF.

Details

Original languageEnglish
Article numbere009766
JournalJournal of the American Heart Association
Volume7
Issue number18
Publication statusPublished - 18 Sep 2018

Keywords

  • atrial fibrillation, bleeding risk, clinical risk scores